



Rare Diseases: Challenges and Treatment

Pietro Matza*

Department of Health Management and Health Economics, University of Oslo, Oslo, Norway

*Corresponding Author: Pietro Matza, Department of Health Management and Health Economics, University of Oslo, Oslo, Norway; E-mail: matza55@nokc.no

Received date: 15 July, 2023, Manuscript No. CICR-23-113233;

Editor assigned date: 17 July, 2023, PreQC No. CICR-23-113233 (PQ);

Reviewed date: 31 July, 2023, QC No. CICR-23-113233;

Revised date: 07 August, 2023, Manuscript No. CICR-23-113233 (R);

Published date: 17 August, 2023, DOI: 10.4172/CICR.1000266

Description

Rare diseases, often referred to as orphan diseases, present a formidable challenge in the field of medicine. These conditions, by definition, affect a limited number of individuals within the population, and many of them are characterized by unique diagnostic challenges and complex treatment modalities. This article explores the intricate landscape of rare diseases, focuses on the difficulties in diagnosis and the innovative approaches to treatment that are transforming the lives of those affected [1].

Understanding rare diseases

Defining rarity: Rare diseases are typically defined as those affecting fewer than 1 in 2,000 individuals. However, this rarity can vary from one region or country to another.

Heterogeneity: The sheer diversity of rare diseases, estimated to number over 7,000, makes them a complex and multifaceted group of conditions. Each may have a unique pathophysiology.

Delayed or Misdiagnosis: Due to their rarity and often atypical presentations, rare diseases are frequently misdiagnosed or diagnosed late, leading to prolonged suffering for patients [2].

Diversity and Complexity of Orphan Diseases

Huntington's disease

Symptoms: The main symptoms are Progressive motor dysfunction, including chorea (involuntary movements) Cognitive decline and psychiatric symptoms, such as depression and irritability, Difficulty in speech and swallowing Muscle rigidity and dystonia, Balance and coordination problems

Cause: Huntington's disease is caused by a genetic mutation in the HTT gene, leading to the production of abnormal proteins that damage brain cells.

Treatment: Currently, there is no cure for Huntington's disease. Treatment focuses on managing symptoms and improving the quality of life. Medications, physical therapy, and support from healthcare professionals play a crucial role in symptom management [3].

Ehlers-Danlos Syndrome (EDS)

Symptoms: The main symptoms of this disease are joint hypermobility and dislocations, skin that is hyperextensible and bruises easily, chronic pain and fatigue, gastrointestinal issues, cardiovascular complications, such as aortic aneurysms.

Cause: EDS is a group of connective tissue disorders caused by various genetic mutations affecting collagen production and structure.

Treatment: Treatment involves symptom management, such as physical therapy for joint stability, pain management strategies, and monitoring for cardiovascular complications [4].

Alkaptonuria

Symptoms: The disease symptoms include, darkening of the urine and connective tissues, referred to as "ochronosis", joint pain and arthritis particularly in large joints, heart valve problems, kidney stones

Cause: Alkaptonuria is an autosomal recessive genetic disorder caused by mutations in the HGD gene, leading to a deficiency in the enzyme homogentisate 1, 2-dioxygenase.

Treatment: Management includes pain relief, physical therapy, and dietary modifications. Investigational treatments, such as nitisinone, are being explored to reduce homogentisic acid production [5].

Hutchinson-Gilford Progeria Syndrome (HGPS)

Symptoms: This syndrome causes rapid aging-like features, including skin tightening and thinning, growth failure and short stature, cardiovascular problems, such as atherosclerosis, musculoskeletal issues and limited mobility

Cause: HGPS is caused by a genetic mutation in the LMNA gene, resulting in the production of a toxic protein called progerin.

Treatment: While there is no cure, treatment focuses on managing symptoms and complications. Cardiovascular monitoring, medication to manage symptoms, and physical therapy are part of the care plan. Experimental drugs targeting progerin production are under investigation [6].

Diagnostic challenges

Genetic variability: A significant proportion of rare diseases have a genetic basis, making genetic testing a crucial diagnostic tool. However, the genetic heterogeneity of these diseases can complicate the diagnostic process.

Lack of awareness: Limited awareness among healthcare providers about rare diseases can result in delayed or missed diagnoses.

Diagnostic odyssey: Patients with rare diseases often endure a diagnostic odyssey, visiting multiple specialists and undergoing numerous tests before receiving a definitive diagnosis [7].

Innovative diagnostic approaches

Next-Generation Sequencing (NGS): NGS technologies have revolutionized the diagnosis of rare genetic diseases by enabling rapid and cost-effective whole-genome or exome sequencing.

Artificial Intelligence (AI): AI algorithms are being developed to analyze medical imaging, genomics, and clinical data, aiding in the identification of rare diseases.

International collaboration: Initiatives like the Undiagnosed Diseases Network (UDN) facilitate collaboration among experts worldwide to solve complex diagnostic cases [8].

Complex treatment modalities

Precision medicine: Tailoring treatments to an individual's genetic makeup has shown promise in managing rare diseases with a genetic basis.

Gene therapies: Advancements in gene therapy offer potential cures for some rare diseases by correcting underlying genetic defects.

Orphan drug development: Incentives for orphan drug development have led to the creation of treatments for rare diseases that were once considered untreatable [9].

Patient advocacy and support

Rare disease communities: Patient advocacy groups and online communities provide vital support networks for individuals and families affected by rare diseases.

Research and funding: Increased research funding and advocacy efforts are driving progress in understanding and treating rare diseases [10].

Conclusion

Rare diseases, with their unique diagnostic challenges and complex treatment modalities, represent an ongoing frontier in medicine. While these conditions continue to pose formidable hurdles, advances in genetics, AI, and international collaboration are providing hope for more and accurate diagnoses. Furthermore, the development of precision treatments and gene therapies is transforming the landscape of rare disease management, offering new possibilities for improved patient outcomes and quality of life. Through continued research,

advocacy, and global cooperation, we move closer to solving the enigma of rare diseases.

References

1. Zadeh KK, Rhee C, Sim JJ, Stenvinkel P, Anker SD, et al. (2013) Why cachexia kills: examining the causality of poor outcomes in wasting conditions. *J Cachexia Sarcopenia Muscle* 4(2); 89–94.
2. Haehling VS, Anker MS, Anker SD (2016) Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016. *J Cachexia Sarcopenia Muscle* 7(5); 507–509.
3. Chapman E (2002) Ethical dilemmas in testing for late onset conditions: Reactions to testing and perceived impact on other family members. *J Genet Couns* 11(5); 351–367.
4. Burls A, Austin D, Moore D (2005) Commissioning for rare diseases: view from the frontline. *BMJ* 331(7523); 1019–1021.
5. Bejerano G, Pheasant M, Makunin I, Stephen S, Kent WJ et al. (2004) Ultra-conserved elements in the human genome. *Science* 304(5675), 1321–1325.
6. Chandra RK, Joglekar S, Antonio Z (1978) Deficiency of humoral immunity and hypoparathyroidism associated with the Hallerman-Streiff syndrome. *J Pediatr* 93(5); 892–893.
7. Jarvis JN, Govender N, Chiller T (2012) Cryptococcal antigen screening and preemptive therapy in patients initiating antiretroviral therapy in resource-limited settings: a proposed algorithm for clinical implementation. *J Int Assoc Physicians AIDS Care* 11(6); 374–379.
8. Martin-Loeches I, J Schultz M, Vincent JL (2017) Increased incidence of co-infection in critically ill patients with influenza. *Intensive Care Med* 43(1); 48–58.
9. McCarthy MW, Petraitiene R, Walsh TJ (2017) Nucleic acid amplification methodologies for the detection of pulmonary mold infections. *Expert Rev Mol Diagn* 17(3); 271–279.
10. Andersson KE (2011) Antimuscarinic mechanisms and the overactive detrusor: An update. *Eur Urol* 59(3); 377–386.